Literature DB >> 1571420

Prenatal diagnosis of intrauterine infection with parvovirus B19 by the polymerase chain reaction technique.

T J Török1, Q Y Wang, G W Gary, C F Yang, T M Finch, L J Anderson.   

Abstract

Human parvovirus B19 is a recently recognized cause of fetal hydrops and death. Efforts to characterize the natural history of fetal infection with this virus have been hampered by the lack of sensitive and specific tests for diagnosis in utero. Using the highly sensitive polymerase chain reaction (PCR) assay, we determined the fetal infection status in 56 pregnancies by testing amniotic fluid, fetal serum, and maternal serum for B19 DNA and antibodies. Factors associated with a high risk of B19 infection were fetal disease, exposure to persons with erythema infectiosum, or signs or symptoms of acute B19 infection. Fifteen women (27%) were B19 IgM-positive, a status suggesting recent infection; the positivity of all of the corresponding fetal specimens for B19 DNA in the PCR was indicative of fetal infection. In four of these cases, serial ultrasonographic examinations documented spontaneous resolution of fetal hydrops. Twenty-four women (43%) were IgG-positive and IgM-negative; this pattern suggested prior infection. The PCR gave positive results, consistent with recent maternal infection, in four of these cases. Seventeen women (30%) were IgG-negative and IgM-negative, a pattern suggesting no prior infection; the PCR results in four cases were indicative of a possible early maternal infection or a possible atypical immune response. The PCR is a sensitive and rapid method for the diagnosis of intrauterine infection with human parvovirus B19 and promises to facilitate studies of the natural history and treatment of this infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571420     DOI: 10.1093/clinids/14.1.149

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

2.  Comparative evaluation of virological and serological methods in prenatal diagnosis of parvovirus B19 fetal hydrops.

Authors:  M Zerbini; M Musiani; G Gentilomi; S Venturoli; G Gallinella; R Morandi
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Determination of normal human fetal immunoglobulin M levels.

Authors:  D J Vick; W A Hogge; D E Normansell; B J Burkett; G M Harbert
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

Review 4.  Parvovirus B19 infection in pregnancy.

Authors:  C J Hall
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-07       Impact factor: 5.747

5.  Prenatal diagnosis of parvovirus B19-induced hydrops fetalis by chemiluminescence in situ hybridization.

Authors:  M Musiani; P Pasini; M Zerbini; G Gentilomi; A Roda; G Gallinella; E Manaresi; S Venturoli
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

6.  Detection of parvovirus B19 in fetal autopsies.

Authors:  T F Schwarz; A Nerlich; P Hillemanns
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

Review 7.  Prenatal diagnosis and significance of fetal infections.

Authors:  A Ghidini; L Lynch
Journal:  West J Med       Date:  1993-09

Review 8.  Parvovirus B-19 infection during pregnancy.

Authors:  Anthony Al-Khan; Andrew Caligiuri; Joseph Apuzzio
Journal:  Infect Dis Obstet Gynecol       Date:  2003

9.  Acute parvovirus B19 infection in pregnant women--an analysis of serial samples by serological and semi-quantitative PCR techniques.

Authors:  K Searle; C Guilliard; S Wallat; G Schalasta; G Enders
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 7.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.